Table 1
Frequently mutated genes identified in 97 TCCs
| Gene | Non-silent somatic changes | Synonymous mutations | Total mutations | N:S ratio | Number (%)of subjects harboring non-silent mutations | P | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Missense | Nonsense, splice site or indel | ||||||
| UTXa | 5 | 17 | 1 | 23 | 22:1 | 20 (21) | 2.22 × 10−37 |
| TP53 | 13 | 8 | 1 | 22 | 21:1 | 20 (21) | 1.01 × 10−49 |
| CREBBPa | 4 | 11 | 2 | 17 | 15:2 | 13 (13) | 3.42 × 10−26 |
| EP300a | 6 | 7 | 0 | 13 | - | 13 (13) | 6.58 × 10−15 |
| ARID1Aa | 4 | 14 | 0 | 18 | - | 13 (13) | 1.99 × 10−32 |
| RB1 | 3 | 8 | 1 | 12 | 11:1 | 11 (11) | 1.00 × 10−11 |
| HRAS | 10 | 0 | 0 | 10 | - | 10 (10) | 7.89 × 10−7 |
| ERBB3 | 9 | 0 | 2 | 11 | 9:2 | 8 (8) | 3.28 × 10−18 |
| CHD6a | 6 | 1 | 2 | 9 | 7:2 | 7 (7) | 6.00 × 10−9 |
| LRP2 | 8 | 1 | 0 | 9 | - | 9 (9) | 4.47 × 10−10 |
| FGFR3 | 9 | 0 | 0 | 9 | - | 9 (9) | 1.69 × 10−18 |
| MLLa | 5 | 3 | 1 | 9 | 8:1 | 7 (7) | 2.00 × 10−11 |
| LAMA4 | 8 | 0 | 1 | 9 | 8:1 | 7 (7) | 4.47 × 10−9 |
| ANK2 | 7 | 0 | 1 | 8 | 7:1 | 7 (7) | 3.07 × 10−8 |
| NF1 | 5 | 2 | 1 | 8 | 7:1 | 7 (7) | 8.76 × 10−10 |
| ESPL1 | 5 | 1 | 1 | 7 | 6:1 | 6 (6) | 2.76 × 10−11 |
| NCOR1a | 5 | 2 | 0 | 7 | – | 6 (6) | 3.21 × 10−6 |
| KRAS | 6 | 0 | 1 | 7 | 6:1 | 6 (6) | 3.29 × 10−26 |
| MLL3a | 2 | 4 | 1 | 7 | 6:1 | 5 (5) | 1.58 × 10−6 |
| ANK3 | 5 | 0 | 1 | 6 | 5:1 | 5 (5) | 9.10 × 10−4 |
| ZFHX3 | 5 | 0 | 0 | 5 | – | 5 (5) | 5.52 × 10−3 |
aChromatin remodeling genes.–, no synonymous mutation was identified in this gene. We confirmed all non-silent somatic changes shown in the table by Sanger sequencing or Sequenom MassARRAY. We calculated P values based on the number of validated non-silent mutations in each gene. Detailed information on each validated mutation is listed in Supplementary Table 5.